Please enable JavaScript to continue using this application.

Compare $RARE vs $SNDX | Chartloom

Compare

$RARE vs $SNDX

Ultragenyx Pharmaceutical Inc · Syndax Pharmaceuticals Inc

RARE

Ultragenyx Pharmaceutical Inc

SNDX

Syndax Pharmaceuticals Inc

Compare $RARE vs $SNDX

Comparing Ultragenyx Pharmaceutical Inc and Syndax Pharmaceuticals Inc

RAREUltragenyx Pharmaceutical Inc

SNDXSyndax Pharmaceuticals Inc

RAREUltragenyx Pharmaceutical Inc

Market cap

$1.52B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.74x

Rev growth (TTM)

17.5%

YTD performance

-34.4%

52W performance

-49.8%

FCF yield

-32.4%

SNDXSyndax Pharmaceuticals Inc

Market cap

$1.51B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

222.7%

YTD performance

-20.2%

52W performance

3.0%

FCF yield

-14.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

RARE

SNDX

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

SNDX

Syndax Pharmaceuticals Inc

Market Cap

RARE$1.52B

SNDX$1.51B

Enterprise Value

RARE$2.54B

SNDX$1.76B

Price

RARE$15.48

SNDX$16.99

P/E Ratio

RAREN/A

SNDXN/A

P/S Ratio

RARE2.13x

SNDX5.97x

EV/Sales

RARE3.54x

SNDX6.97x

EV/EBITDA

RARE0.00x

SNDX1,613.51x

P/B Ratio

RARE163.83x

SNDX104.09x

P/FCF Ratio

RAREN/A

SNDXN/A

EV/FCF

RARE-5.14x

SNDX-7.96x

PEG Ratio

RAREN/A

SNDXN/A

Forward P/E (NTM)

RAREN/A

SNDXN/A

Forward P/S (NTM)

RARE1.74x

SNDXN/A

Revenue (TTM)

RARE$717M

SNDX$252M

Revenue Growth (YoY)

RARE17.5%

SNDX222.7%

Forward Rev Growth

RARE27.7%

SNDX41.0%

Gross Margin (TTM)

RARE83.1%

SNDX95.8%

Operating Margin (TTM)

RARE0.0%

SNDX0.0%

EBITDA Margin (TTM)

RARE-69.0%

SNDX-77.0%

Net Margin (TTM)

RARE-81.7%

SNDX-87.5%

FCF Margin (TTM)

RARE-68.9%

SNDX-87.6%

Net Income (TTM)

RARE$-586M

SNDX$-221M

FCF (TTM)

RARE$-494M

SNDX$-221M

EPS (TTM)

RARE-$5.75

SNDX-$2.48

ROE (TTM)

RARE-41417.0%

SNDX-37294.0%

ROA (TTM)

RARE-4437.0%

SNDX-3911.0%

ROIC (TTM)

RARE-5861.0%

SNDX-4756.0%

Cash

RARE$125M

SNDX$336M

Debt

RARE$1.14B

SNDX$588M

Net Cash/Debt

RARE$-1.02B

SNDX$-252M

Current Ratio (TTM)

RARE1.73x

SNDX6.77x

Quick Ratio (TTM)

RARE1.43x

SNDX6.32x

Debt/Equity (TTM)

RARE90.54x

SNDX38.95x

Debt/Assets (TTM)

RARE0.0%

SNDX0.0%

Interest Coverage (TTM)

RAREN/A

SNDXN/A

Net Debt/EBITDA (TTM)

RARE0.00x

SNDX0.00x

Beta

RARE0.35

SNDX0.40

52W Performance

RARE-49.8%

SNDX3.0%

YTD Performance

RARE-34.4%

SNDX-20.2%

% from 52W High

RARE-61.2%

SNDX-33.6%

% from 52W Low

RARE21.6%

SNDX30.8%

Asset Turnover (TTM)

RARE0.54x

SNDX0.45x

FCF Yield (TTM)

RARE-32.4%

SNDX-14.7%

Earnings Yield (TTM)

RARE-38.4%

SNDX-14.7%

Dividend Yield (TTM)

RAREN/A

SNDXN/A

Rule of 40

RARE-51.4

SNDX135.1

EV/GP/RG

RARE0.17

SNDX0.15

Ticker research

View RARE research View SNDX research

Metric	RARE Ultragenyx Pharmaceutical Inc	SNDX Syndax Pharmaceuticals Inc
Market & Valuation
Market Cap	$1.52B	$1.51B
Enterprise Value	$2.54B	$1.76B
Price	$15.48	$16.99
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	5.97x
EV/Sales	3.54x	6.97x
EV/EBITDA	0.00x	1,613.51x
P/B Ratio	163.83x	104.09x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-7.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	N/A
Revenue & Growth
Revenue (TTM)	$717M	$252M
Revenue Growth (YoY)	17.5%	222.7%
Forward Rev Growth	27.7%	41.0%
Profitability
Gross Margin (TTM)	83.1%	95.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-77.0%
Net Margin (TTM)	-81.7%	-87.5%
FCF Margin (TTM)	-68.9%	-87.6%
Net Income (TTM)	$-586M	$-221M
FCF (TTM)	$-494M	$-221M
EPS (TTM)	-$5.75	-$2.48
ROE (TTM)	-41417.0%	-37294.0%
ROA (TTM)	-4437.0%	-3911.0%
ROIC (TTM)	-5861.0%	-4756.0%
Financial Health
Cash	$125M	$336M
Debt	$1.14B	$588M
Net Cash/Debt	$-1.02B	$-252M
Current Ratio (TTM)	1.73x	6.77x
Quick Ratio (TTM)	1.43x	6.32x
Debt/Equity (TTM)	90.54x	38.95x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	0.40
52W Performance	-49.8%	3.0%
YTD Performance	-34.4%	-20.2%
% from 52W High	-61.2%	-33.6%
% from 52W Low	21.6%	30.8%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.45x
FCF Yield (TTM)	-32.4%	-14.7%
Earnings Yield (TTM)	-38.4%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	135.1
EV/GP/RG	0.17	0.15
Ticker research	View RARE research	View SNDX research

Valuation

P/S Ratio

RARE

2.13x

SNDX

5.97x

EV/FCF

SNDX

-7.96x

RARE

-5.14x

Growth & revenue

Revenue Growth TTM

SNDX

222.7%

RARE

17.5%

Forward Revenue Growth

SNDX

41.0%

RARE

27.7%

Profitability & performance

Gross Margin

SNDX

95.8%

RARE

83.1%

ROE

SNDX

-37294.0%

RARE

-41417.0%

FCF Yield %

SNDX

-14.7%

RARE

-32.4%

52-Week Performance

SNDX

3.0%

RARE

-49.8%

Detailed metrics comparison

RARE

Ultragenyx Pharmaceutical Inc

SNDX

Syndax Pharmaceuticals Inc

Market Cap

RARE$1.52B

SNDX$1.51B

Enterprise Value

RARE$2.54B

SNDX$1.76B

Price

RARE$15.48

SNDX$16.99

P/E Ratio

RAREN/A

SNDXN/A

P/S Ratio

RARE2.13x

SNDX5.97x

EV/Sales

RARE3.54x

SNDX6.97x

EV/EBITDA

RARE0.00x

SNDX1,613.51x

P/B Ratio

RARE163.83x

SNDX104.09x

P/FCF Ratio

RAREN/A

SNDXN/A

EV/FCF

RARE-5.14x

SNDX-7.96x

PEG Ratio

RAREN/A

SNDXN/A

Forward P/E (NTM)

RAREN/A

SNDXN/A

Forward P/S (NTM)

RARE1.74x

SNDXN/A

Revenue (TTM)

RARE$717M

SNDX$252M

Revenue Growth (YoY)

RARE17.5%

SNDX222.7%

Forward Rev Growth

RARE27.7%

SNDX41.0%

Gross Margin (TTM)

RARE83.1%

SNDX95.8%

Operating Margin (TTM)

RARE0.0%

SNDX0.0%

EBITDA Margin (TTM)

RARE-69.0%

SNDX-77.0%

Net Margin (TTM)

RARE-81.7%

SNDX-87.5%

FCF Margin (TTM)

RARE-68.9%

SNDX-87.6%

Net Income (TTM)

RARE$-586M

SNDX$-221M

FCF (TTM)

RARE$-494M

SNDX$-221M

EPS (TTM)

RARE-$5.75

SNDX-$2.48

ROE (TTM)

RARE-41417.0%

SNDX-37294.0%

ROA (TTM)

RARE-4437.0%

SNDX-3911.0%

ROIC (TTM)

RARE-5861.0%

SNDX-4756.0%

Cash

RARE$125M

SNDX$336M

Debt

RARE$1.14B

SNDX$588M

Net Cash/Debt

RARE$-1.02B

SNDX$-252M

Current Ratio (TTM)

RARE1.73x

SNDX6.77x

Quick Ratio (TTM)

RARE1.43x

SNDX6.32x

Debt/Equity (TTM)

RARE90.54x

SNDX38.95x

Debt/Assets (TTM)

RARE0.0%

SNDX0.0%

Interest Coverage (TTM)

RAREN/A

SNDXN/A

Net Debt/EBITDA (TTM)

RARE0.00x

SNDX0.00x

Beta

RARE0.35

SNDX0.40

52W Performance

RARE-49.8%

SNDX3.0%

YTD Performance

RARE-34.4%

SNDX-20.2%

% from 52W High

RARE-61.2%

SNDX-33.6%

% from 52W Low

RARE21.6%

SNDX30.8%

Asset Turnover (TTM)

RARE0.54x

SNDX0.45x

FCF Yield (TTM)

RARE-32.4%

SNDX-14.7%

Earnings Yield (TTM)

RARE-38.4%

SNDX-14.7%

Dividend Yield (TTM)

RAREN/A

SNDXN/A

Rule of 40

RARE-51.4

SNDX135.1

EV/GP/RG

RARE0.17

SNDX0.15

Ticker research

View RARE research View SNDX research

Metric	RARE Ultragenyx Pharmaceutical Inc	SNDX Syndax Pharmaceuticals Inc
Market & Valuation
Market Cap	$1.52B	$1.51B
Enterprise Value	$2.54B	$1.76B
Price	$15.48	$16.99
P/E Ratio	N/A	N/A
P/S Ratio	2.13x	5.97x
EV/Sales	3.54x	6.97x
EV/EBITDA	0.00x	1,613.51x
P/B Ratio	163.83x	104.09x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.14x	-7.96x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.74x	N/A
Revenue & Growth
Revenue (TTM)	$717M	$252M
Revenue Growth (YoY)	17.5%	222.7%
Forward Rev Growth	27.7%	41.0%
Profitability
Gross Margin (TTM)	83.1%	95.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-69.0%	-77.0%
Net Margin (TTM)	-81.7%	-87.5%
FCF Margin (TTM)	-68.9%	-87.6%
Net Income (TTM)	$-586M	$-221M
FCF (TTM)	$-494M	$-221M
EPS (TTM)	-$5.75	-$2.48
ROE (TTM)	-41417.0%	-37294.0%
ROA (TTM)	-4437.0%	-3911.0%
ROIC (TTM)	-5861.0%	-4756.0%
Financial Health
Cash	$125M	$336M
Debt	$1.14B	$588M
Net Cash/Debt	$-1.02B	$-252M
Current Ratio (TTM)	1.73x	6.77x
Quick Ratio (TTM)	1.43x	6.32x
Debt/Equity (TTM)	90.54x	38.95x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.35	0.40
52W Performance	-49.8%	3.0%
YTD Performance	-34.4%	-20.2%
% from 52W High	-61.2%	-33.6%
% from 52W Low	21.6%	30.8%
Efficiency & Yields
Asset Turnover (TTM)	0.54x	0.45x
FCF Yield (TTM)	-32.4%	-14.7%
Earnings Yield (TTM)	-38.4%	-14.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-51.4	135.1
EV/GP/RG	0.17	0.15
Ticker research	View RARE research	View SNDX research